Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
7
Bullish
5
Bearish
16
Neutral
11
Bullish
19
Bearish
14
Neutral
4
Bullish
14
Discovery themes featuring this stock
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products.
The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India.
Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS.
Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts.
Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
72 Cr
Low Risk
16.4
44.0
—
2.8
35.52
10.56
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Kabra Drugs Ltd (KABRADG) is currently trading at 30.37 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products. The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India. Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS. Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts. Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Over the past 52 weeks, Kabra Drugs Ltd has traded between a low of ₹10.56 and a high of ₹35.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kabra Drugs Ltd has a market capitalization of approximately 71.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kabra Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.42 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 71.72 Cr, Kabra Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kabra Drugs Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kabra Drugs Ltd is 16.42. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
792.30 | 95 Cr | 20.16 | 1.70 | 0.44 | 8.81 | 11.49 | 6.38 | |
46.00 | 84 Cr | 8.17 | 1.35 | 0.00 | 15.41 | 18.92 | 6.93 | |
140.00 | 84 Cr | 68.29 | 1.18 | 0.00 | -0.03 | 8.67 | 3.76 | |
16.93 | 74 Cr | -4.05 | 0.00 | 0.00 | -22.95 | -11.16 | -9.61 | |
30.37 | 72 Cr | 16.42 | 2.76 | 0.00 | 4.59 | 5.90 | 7.89 | |
31.31 | 49 Cr | 18.42 | 2.32 | 0.00 | 13.42 | 15.83 | 5.00 | |
24.75 | 43 Cr | 106.22 | 2.52 | 0.00 | 4.40 | 4.69 | 3.53 |
Board Meeting Intimation
Kabra Drugs will hold a Board meeting on 07-Mar-2026 in Chennai to consider a proposed company name change (subject to shareholder/MCA approval), discuss strategic expansion into Indonesia and Canada, and other business.
Board Meeting Intimation
Kabra Drugs Ltd informed BSE that its Board will meet on 07‑Mar‑2026 in Chennai to consider a company name change (subject to shareholder/MCA approval), approve strategic expansion into Indonesia and Canada, and other business.
